From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker - Sanofi (NASDAQ:SNY)

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker - Sanofi (NASDAQ:SNY)

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

Sanofi immune drug hopeful posts mixed results in mid-stage tests

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

Sanofi’s bispecific scores in respiratory diseases but fails in eczema

Sanofi’s lunsekimig met its endpoints in asthma and CRSwNP but missed the primary endpoint in eczema.The post Sanofi’s bispecific scores in respiratory diseases but fails in eczema appeared first on Clinical Trials Arena.

Sanofi Highlights Potential of Lunsekimig as New Treatment Option Following Strong Phase 2 Study Outcomes

Open the article to view the coverage from EuropaWire.eu

Sanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczema

Sanofi reported a mixed set of mid-stage data for its immunology drug that was designed to improve upon Dupixent and AstraZeneca’s Tezspire. The French drugmaker said Tuesday its bispecific nanobody, called ...